DOWNLOAD FLYER HERE

ProAssurance is proud to sponsor this live CME presentation for MDs/DOs. 

This live educational activity will support your ability to:

• Identify the use of GLP-1 agonists (semaglutide and tirzepatide) in treating diabetes, obesity and
  cardiometabolic conditions;
• Use of GLP-1 agonists for cardiovascular disease prevention
• Discuss additional uses such as
• Current research for other applications
• Practical information on when it’s appropriate to order use of GLP-1 agonist in treatment
• Most common side effects of GLP-1 and dual agonists

Presenter:
Ricardo Correa, M.D., Ed. D., F.A.C.E., F.A.C.P., F.A.C.M.Q.; Program Director for Endocrinology, Diabetes and Metabolism Fellowship; Director, Health Equity Center, The Cleveland Clinic, Ohio; Clinical Professor of Medicine, Director for Longitudinal Didactics and Director for DEI on Mentoring of Cleveland Clinic Lerner College of Medicine 

Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Loma Linda University School of Medicine and San Bernardino County Medical Societ.  The Loma Linda University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.The Loma Linda University School of Medicine designates this Live Activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement:
This program has been planned and implemented in accordance with ACCME Standards for Integrity and Independence. The Loma Linda University School of Medicine Office of Continuing Medical Education relies on its CME faculty to provide program content that is free of commercial bias. Therefore, in  accordance with ACCME standards, any faculty and/or provider industry relationships will be disclosed and resolved.